Ewing's sarcoma: surgical resection as a prognostic factor. 1988

S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
Dept. of Radiation Medicine, Massachusetts General Hospital, Boston.

A retrospective review of 46 cases of Ewing's (43) and extraosseous Ewing's (3) sarcoma was performed to examine for prognostic factors. Follow-up ranged from 27 to 135 months with a mean of 77.6 months, 86% greater than 36 months. Nine (20%) patients presented with distant metastases, 98% received multiagent chemotherapy, and 98% received radiation therapy. Overall actuarial survival and local control at 5 years were .52 +/- .08 and .78 +/- .07, respectively. The freedom from relapse or treatment related mortality at 5 years was .46 +/- .08. In 12 (26%) patients, surgical resection of the involved bone or soft tissue was part of the initial treatment plan. Ninety-two percent (11/12) of these patients also received radiation therapy. In addition to surgical resection, tumor size (less than 500 cc vs. greater than or equal to 500 cc), primary site (central vs. other), and stage were also analyzed for prognostic significance, and where appropriate, were included in Cox multivariate analyses. Considering all patients, the 5-year actuarial survival was .92 +/- .08 vs. .37 +/- .09 for patients receiving and not receiving surgical resection, respectively (p = .001 by logrank, p = .02 by Cox). To make the groups more comparable, 8 patients with local failure and 5 patients with non-evaluable primary sites were excluded. After these exclusions, the presence or absence of surgical resection had decreased significance: .92 +/- .08 vs. .59 +/- .11, respectively; p = .01 by logrank, p = .07 by Cox. Only primary site remained statistically significant: .86 +/- .08 for noncentral sites vs. .38 +/- .16 for central sites, p less than .0002 by logrank, p = .0004 by Cox. Surgical resection when added to local irradiation has prognostic significance in this retrospective review. The reason for this is not clear, but may be related to a decrease in local failure after resection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
September 2012, Journal of surgical oncology,
S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
September 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
April 1985, European journal of cancer & clinical oncology,
S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
April 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
July 2010, Lancet (London, England),
S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
January 2021, BioMed research international,
S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
June 2023, BMJ case reports,
S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
January 1984, Bulletin du cancer,
S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
April 2009, Clinical cancer research : an official journal of the American Association for Cancer Research,
S L Sailer, and D C Harmon, and H J Mankin, and J T Truman, and H D Suit
April 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!